Ballicules.com

Alfuzosin

UROXATRAL

Pronunciation: al-FYOO-zoe-sin (yoo-ROX-a-tral)

Alfuzosin ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Alfuzosin ballicule

What it isAlpha-1 antagonist with functional uroselectivity; benign prostatic hyperplasia.

Why this oneLess ejaculatory dysfunction than tamsulosin, and no titration is needed.

What limits itOrthostatic hypotension and QT prolongation. CYP3A4-dependent, so strong inhibitors are contraindicated.

Alfuzosin molecular structure (skeletal formula)
Molecular structure: Alfuzosin

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Benign prostatic hyperplasiaMen10 mg QD with food (same meal each day)10 mg QD

Renal Use with caution in severe impairment (CrCl <30 mL/min); no specific dose adjustment

Hepatic Contraindicated in moderate-severe impairment (Child-Pugh B/C); use caution in mild (not studied)

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy Not indicated for use in women.

Lactation Not indicated for use in women.

Cost

Alfuzosin (UROXATRAL)
What pharmacies pay · NADAC 9/30/26
Strength#/mogeneric $/moCostPlus
10 mgER tab30 qd$3.15offered

Generic entry2011

NO BOXED WARNINGS

Principal riskOrthostatic hypotension; QT prolongation

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades1 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryC

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Open Alfuzosin in the interactive console ↗